TriangleLoncastuximab Tesirine (NCT05464719)
Loncastuximab Tesirine trial for Large B-cell Lymphoma (NCT05464719). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed/refractory large B-cell lymphomas showing a partial response thirty days after commercial CD19 CAR T-cell therapy. Previous loncastuximab and active CNS lymphoma are excluded.
The idea: loncastuximab tesirine carries a DNA-crosslinking payload to CD19-bearing cells. Patients receive infusions as consolidation after CAR T-cell treatment. Researchers measure conversion to complete response, safety, and biomarkers. Post-CAR-T proof of CD19 expression is not required; prior cytokine-release and neurological toxicities must resolve.
This phase 2 study plans 30 patients. Paolo Strati leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.